Pharmacogenomic databases of drug response and genomics data in tumor cell lines allow the development of pan-cancer (i.e. tissue-agnostic) predictions of drug response. However, it is unclear whether between-tissue differences in both drug response and molecular characteristics bias pan-cancer drug response predictions. Using two datasets containing 346 and 504 cell lines with MEK inhibitor (MEKi) response data and RNA, SNP, and CNV data, we show between-tissue differences produced confounding effects that increase apparent performance in pan-cancer MEKi response predictions. We estimate that 45-58% of the variance in pan-cancer prediction scores was driven by accurate betweentissue predictions, rather than inter-individual predictions within a tissue. Nevertheless, MEKi response is predicted as well or better by pan-cancer approaches compared to tissue-specific approaches. Our results demonstrate strong between-tissue effects in tissue-agnostic drug response prediction models, but also highlight how drug response may invoke shared regulatory mechanisms although different cancer types arise in tissue-specific routes.
INTRODUCTION
Tailoring cancer treatment to the molecular vulnerabilities of individual tumors represents a central goal of precision oncology (1) (2) (3) . Public repositories of drug response and functional genomics data have facilitated the identification of DNA mutations in well-characterized cancer genes that underlie variable drug response (3, 4) , and have expanded to unbiased searches for such biomarkers across the human genome (4, 5) . More recent drug response prediction analyses have further incorporated data modalities beyond DNA variants, e.g. gene expression, metabolomics (4, 6, 7) . Drug response predictions based on molecular characteristics of primary tumors and auxiliary models are frequently performed within a single cancer type or subtype, as tumors from the same primary tissue are generally expected to harbor shared molecular vulnerabilities to anti-cancer agentspresumably as a result of tissue-specific oncogenic processes. Alternatively, drug response predictions can be developed by considering multiple cancer types jointly, i.e., through pan-cancer analyses. The success of pan-cancer prediction models would suggest diverse cancer types share molecular vulnerabilities despite tissue-specific mechanisms of cancer initiation, progression, or drug-response.
Pharmacogenomic databases of patient-derived cancer cell lines covering a broad range of cancer types represent reusable pre-clinical models for deep interrogation of the cell lines' innate characteristics that account for their drug response profiles (8) (9) (10) (11) (12) . Using tumor cell line resources, DNA variants and gene expression levels have been used to develop pan-cancer drug-response prediction models via a wide variety of computational methods, including regularized regression (8, 13) , random forests (14, 15) , neural networks (16) , network modeling (17, 18) , quantitative structure-activity relationship analysis (19) , and deep learning (20) . These analyses have also offered many additional insights, including the importance of RNA expression for pan-cancer predictions (14) , higher accuracy of multi-gene classifiers (i.e. gene panels) compared to single-gene classifiers (15) , and the suitability of cell lines as in vitro mimics of primary tumors (13, 14) .
Despite the reported progress of pan-cancer drug response predictions, it remains unclear whether between-tissue differences could have contributed to the apparent prediction performance. This concern stems from the observation that some cancer types may be more sensitive to a certain drug than others, and their tissue-specific molecular properties may drive performance of a pan-cancer panel without accounting for inter-tumor differences within a cancer type. While cancer type-based therapeutic decisions are useful in clinical practice, there is often the additional need to predict variable response among tumors within a cancer type. We set out to examine the relative importance of between-and within-cancer type signals in pan-cancer drug response prediction models. Further, a systematic investigation into whether pan-cancer approaches are more accurate than drug response predictions tailored to specific cancer types or subtypes is currently unavailable. Here, we analyzed data from ten cancer types that were well-represented in two public cell line datasets (11, 12) and examined the between-tissue and within-tissue performances of pan-cancer drug response predictions for MEK inhibition. In addition to investigating tissue-level effects, we evaluated cross-MEK inhibitor prediction models and provided in silico replication by applying prediction models across datasets. Based on our results, we highlight key considerations for deploying pan-cancer drug response prediction frameworks.
RESULTS

MEK inhibitor sensitivity across cancer types in two public cell line datasets
To evaluate pan-cancer drug response predictions in pre-clinical tumor models, we utilized publicly available datasets of tumor cell lines from a prior publication (referred to as Klijn 2015) (11) and the Cancer Cell Line Encyclopedia database (CCLE) (12) . Klijn 2015 and CCLE include 349 and 503 tumor cell lines from >10 cancer types (Figure 1A) , respectively, that have drug response data and RNA and DNA characterization, with 154 cell lines in common between the two datasets ( Figure 1B) . Among the 5 and 24 drugs screened in Klijn 2015 and CCLE datasets, respectively, MEK inhibition was the sole mechanism of action in common, with one MEK inhibitor (MEKi) present in both datasets (PD-0325901; referred to as PD-901) and an additional MEKi unique to each dataset (Klijn 2015: GDC-0973; CCLE: Selumetinib). We therefore prioritized predicting MEKi response, as prediction models could be evaluated for consistency across both Klijn 2015 and CCLE datasets. Moreover, MEK inhibition has shown promise for pan-cancer drug response predictions (14) . copy number variations (CNVs; n=4,578 mutated genes; SNP microarray). We mapped SNP and CNV features to the gene level, where they indicated whether an annotated gene contained a coding SNP (binary; gene mutated vs. gene not mutated) or was duplicated/deleted (gene amplified vs. gene deleted vs. no CNV). SNPs included only missense and nonsense mutations and SNPs and CNVs were filtered for known germline variants, but likely contained a mixture of germline and somatic mutations.
First, we compared MEKi responses of individual cell lines across cancer types and found clear differences. Skin, pancreatic, and colorectal cell lines were generally sensitive to MEK inhibition, while lymphoid, brain, ovary, and breast cell lines were generally resistant ( Figure 1C) . We also observed cancer types with more mixed responses to MEKi, including lung, stomach, and liver ( Figure 1C) . For cancer types with mixed response, i.e. wide range of drug responses observed within a cancer type, it is challenging to make treatment decisions based on cancer type alone and there is enormous value and opportunity to develop molecular predictors for individualized prediction. We further compared how similar the 154 cell lines in common between Klijn 2015 and CCLE responded to different MEK inhibitors. MEKi response in overlapping cell lines was highly correlated across distinct MEKi and between datasets (Spearman's =0.65 to 0.88; Figure 1D ). The observation that cell lines respond similarly to different MEK inhibitors indicates cross-MEKi predictions are feasible, provided the two compounds are chemically similar.
We also compared gene expression profiles between cancer types in each of the two datasets with principal component analysis (PCA) on standardized RNA expression levels (see Methods; Figure 1E ).
Cell lines from Klijn 2015 and CCLE were present in overlapping distributions in PC1/PC2 space ( Figure 1E) , a characteristic that we took advantage of to apply prediction models across datasets (see below). Cell lines from the same primary tissue tend to be present in similar regions of the PC1/PC2 space ( Figure 1E ) and have correlated RNA expression levels (Figure S1 ), highlighting that cell lines derived from the same primary tissue have similar transcriptomic features. Given the effects of primary tissue on both response to MEK inhibition ( Figure 1C ) and transcriptomic profiles (Figure 1E ; Figure   S1 ), it is plausible that between-tissue differences will be modeled in pan-cancer drug response predictions that consider RNA data, even in cases where tissue labels are not included in a prediction model. The Klijn 2015 and CCLE datasets provide the needed resources to establish pan-cancer MEKi drug response predictions and investigate possible tissue-level confounding factors.
Pan-cancer machine learning predictions of MEK inhibitor sensitivity
With the data described in the previous section, one can establish the molecular features most strongly correlated with drug response, and further, develop predictors of drug response consisting of multiple molecular features. For the latter, we adopted two ways of using the drug response variables by either taking log(IC50) as a continuous variable or dichotomizing drug response to a binary variable. For the former (continuous variables), we developed prediction models using regularized regression and random forest regression algorithms; and for the later (dichotomized variables), we adopted logistic regression and binary random forest algorithms. In total, four prediction algorithms were used. For each algorithm, we developed prediction models by considering the drug response data for one MEKi along with associated molecular featurese.g. response to PD-901 as assessed by Klijn 2015 compared with the Klijn 2015 molecular features (Figure 2A ). One prediction model was built for each MEKi in both datasets, resulting in four prediction models per algorithm, and models were applied both within and between the Klijn 2015 and CCLE datasets. To assess performance, we established two validation sets: 1) for within-dataset predictions, model performance was reported for the 154 cell lines in common between the two datasets, which were excluded during all aspects of model generation and 2) for between-dataset predictions, performance was reported across all cell lines as no cell lines in the dataset the model was applied to were used during model development. An example schematic of model training while considering PD-901 in the Klijn 2015 dataset and model application both within and across datasets is shown in Figure 2A . Figure 2C ). Our results are therefore consistent with those previous that show response to anti-cancer drugs can be successfully predicted based on pan-cancer datasets (8, 14, 15, 20, 21) , and our framework allowed us to further assess cross-MEKi and cross-dataset predictions.
With a set of pan-cancer MEKi response predictions, we assessed the performance of individual machine learning algorithms from the perspectives of cross-MEKi and cross-dataset predictions. Random forest models (both regression and binary) that were trained while considering Selumetinib and CCLE RNA and DNA features exhibited lower performance relative to other algorithms and training sets (y(C2) in Figure 2C ). Otherwise, regularized regression and logistic regression algorithms performed similarly (Mann Whitney U test, all p ≥ 0.86; Figure 2C ). We also found that models built with one MEKi . Cell lines in common between the two datasets were excluded from model building. Prediction models were built on 70% of available cell lines (selected randomly), repeated 30 times, and the final predicted drug response of a given cell line was calculated as the average of the 30 models. Note that the remaining 30% of cell lines that were not selected for model training were not used to assess model performance. The resulting prediction models are applied to within-dataset and across-dataset RNA and DNA data (xK and xC) to generate predicted drug response scores (y(K1)). Predicted drug response values were then compared with observed drug response to evaluate model performance (within-dataset: yK1 vs. y(K1); cross-dataset: yC2 vs. y(K1)). (B) Tissue-of-origin, observed MEKi response, and normalized MEKi predicted response from regularized regression and logistic regression algorithms for the 154 cell lines in common between Klijn 2015 (left panel) and CCLE (right panel). Two magenta boxes highlight scores from four regularized regression models applied to the Klijn 2015 data (y(K1) to y(C2)) and compared with observed response to PD-901 in Klijn 2015 (yK1). Two cyan boxes highlight the scores from four logistic regression models applied to the CCLE data (y(K1) to y(C2)) and compared with observed response to Selumetinib in CCLE (yC2). (C) Performance by Spearman's  (left panel) and area under the receiver operating characteristic curve (auROC; right panel) for all combinations of observed and predicted MEKi response and molecular features from both datasets, for two regression-based algorithms (regularized and random forest) and two binary classification algorithms (logistic and random forest). auROC was calculated by classifying cell lines with IC50 ≤ 1 µM and IC50 > 1 µM as separate classes (sensitive and resistant, respectively). Magenta and cyan boxes indicate the performance metrics resulting from the color-matched comparisons in (B). RF: random forest.
Between-and within-tissue performance of pan-cancer MEKi response predictions
We evaluated how predicted MEKi responses differ across cancer types by averaging predicted values of cell lines and assessing performance within each of 10 cancer types. We found that mean observed and mean predicted log(IC50) values for cell lines derived from the same primary tissue were highly correlated across tissues ( range: 0.88-0.98; Figure 3A ; Figure S2A ). Pan-cancer prediction models are therefore accurately capturing average drug responses of tissues, as tissues that tend to be sensitive or resistant to MEK inhibition exhibited generally low or high prediction scores, respectively.
We next calculated within-tissue performance metrics from pan-cancer prediction models by considering only cell lines from a single cancer type ( Figure 3A; Figure S2B ). Based on hierarchical clustering of the resulting within-tissue prediction performances, we identify five tissues whose response to MEK inhibition was accurately predicted by pan-cancer prediction models: liver, ovary, lymphoid, stomach, and skin (mean  = 0.59;  range: 0.51-0.64; Figure S2B ). The remaining five tissues (pancreas, brain, colorectal, breast, and lung) exhibited lower prediction performance (mean  = 0.28;  range: 0.11-0.40; Figure S2B ). We conclude that whether a pan-cancer MEKi response prediction approach can be considered viable will vary based on which tissue is considered, with half of the tissues evaluated here achieving successful inter-individual predictions ( ≥ 0.51).
Accurate between-tissue drug response predictions can improve performance metrics when cell lines from different tissues are considered together, even in cases where within-tissue predictions fail. To illustrate this phenomenon, we show the prediction performance for a combination of two tissues: brain and pancreas (Figure 3B) . Within-tissue performances from pan-cancer predictions for both brain and pancreas cell lines are poor (both  ≤ 0.1; Figure 3B ; Figure S2B ). However, prediction performance increased dramatically when the two tissues are considered together ( = 0.48; Figure 3B ), as both observed and predicted log(IC50) for pancreas cell lines are low on average, while both observed and predicted log(IC50) for brain cell lines are high. Thus, accurate between-tissue predictions can erroneously inflate performance metrics when multiple tissues are considered together.
To estimate the effect of accurate between-tissue predictions on the overall performance of the pan-cancer predictions, we developed a set of MEKi response prediction scores based on tissue-of-origin, Figure 3 . Performance of pan-cancer MEKi response predictions within cancer types. (A) Visualization of within-tissue mean observed and mean predicted log(IC50) values from pan-cancer prediction models along with within-tissue pan-cancer prediction performance (Fig. 2) . Dots at the center of ellipses indicate the mean observed and predicted log(IC50) values for a given tissue. Maximum ellipsis length scales with the range of MEKi responses for a given tissue, where tissues with larger response ranges are associated with larger ellipses (e.g. stomach) while tissues with a smaller response range are associated with smaller ellipses (e.g. breast). The slope of dashed lines, as well as the tilt and width of associated ellipses, correspond to within-tissue prediction performance of the pan-cancer prediction model. Lines at angles closer to 45° and thinner ellipses (more cigar shaped) both indicate better prediction performances. (B) Performance of pan-cancer prediction models for a combination of brain and pancreas tissues. Rank correlation (Spearman's ) is shown for brain cell lines (gray), pancreas cell lines (purple), and both brain and pancreas combined (black). Dashed lines indicate lines of best fit. The increase in performance for the combined tissues (=0.48) compared to each individual tissue (both <0.10) highlights the confounding effect that accurate between-tissue predictions can exert on overall prediction performance. (C) Performance of predictions after shuffling existing pan-cancer prediction scores (Fig. 2) within a cancer type 100 times (gray points; e.g. a lung cell line was randomly assigned the prediction score of a different lung cell line). Vertical black lines: median performance from 100 iterations of shuffling scores within tissues. Red points: performance when scores are not shuffled. The percentages on the left side are calculated by median tissue-shuffled performance / non-shuffled performance × 100. The percentage is interpreted as the proportion of variance in pan-cancer MEKi response scores that can be attributed to accurate between-tissue predictions, rather than inter-individual predictions. rather than individual tumor characteristics. Tissue-based prediction scores were generated by shuffling existing MEKi prediction scores within tissues (i.e. a lung cell line randomly assigned the existing prediction score from another lung cell line). As a result, any tissue-scale effects within the prediction model will be maintained, while the effects from characteristics of individual tumors are necessarily lost.
The performance of the resulting tissue-shuffled prediction scores across all 10 tissues were compared to non-shuffled prediction performance (Figure 3C) . For regularized regression predictions, the mean rank correlation between observed log(IC50) and tissue-shuffled scores is 0.32, while the mean non-shuffled correlation was 0.61. Similar results are also observed for logistic regression predictions (mean tissueshuffled auROC=0.65; mean non-shuffled auROC=0.83; Figure S2C ). Overall, depending on algorithm and training/testing set, we found that performance metrics from tissue-shuffled predictions are 42% to 58% lower than those from non-shuffled predictions (Figure 3C; Figure S2C ). We therefore conclude that roughly half of the performance of the pan-cancer MEKi response predictions developed here can be attributed to accurate between-tissue MEKi response predictions, rather than prediction of inter-individual differences within a tissue.
Comparisons of pan-cancer and tissue-specific MEKi response predictions
Consistent with previous studies (8, 14, 15, 20, 21) , we demonstrated that pan-cancer predictions of drug sensitivity can be successful (Figure 2) . However, it is unknown whether pan-cancer prediction models can outperform those generated by considering a single cancer type. To address this question, we carried out a systematic comparison of tissue-specific prediction models (i.e. trained and tested with cell lines from a single cancer type) and pan-cancer prediction results for the same 10 cancer types (Figure 4) .
As models were developed within a single cancer type, fewer cell lines are available compared to pancancer models. Due to these sample size constraints, we considered only regularized regression prediction models trained on CCLE data, which includes more cell lines, with models applied cross-dataset to Klijn 2015 data.
Based on these comparisons, we found that pan-cancer MEKi response predictions performed similarly or better than tissue-specific predictions for 9 out of 10 tissues (Figure 4A-D) . Pancreas was the only tissue for which tissue-specific prediction models outperformed pan-cancer models and the performance of pancreas predictions was generally low, and varied based on training data (Figure 4A-D) .
An important caveat is that pan-cancer prediction models were trained while considering 4-to 28-fold more cell lines than tissue-specific prediction models (e.g. training set size of 68 lung and 12 liver cell lines for tissue-specific models). To account for differences in sample sizes between pan-cancer and tissue-specific predictions, we trained an additional set of pan-cancer prediction models that considered downsampled sets of cell lines equal in size to the training set of the tissue-specific models ("Pan-cancer (downsampled)" in Figure 4) . These downsampled pan-cancer prediction models rarely outperformed tissue-specific predictions and then, only in cases where tissue-specific models perform particularly poorly (e.g. skin; Figure 4) . Unsurprisingly, downsampled pan-cancer prediction models performed worse (95 th percentile =0.2) than full pan-cancer prediction models (95 th percentile =0.67; Figure 4 ).
Overall, we find that the accuracy of pan-cancer prediction models relative to tissue-specific models highlights the potential of pan-cancer approaches as tools for precision oncology. However, we emphasize that when pan-cancer prediction models outperform tissue-specific models, it is due to sample sizes available from large pan-cancer datasets.
Estimating sample sizes required for optimal prediction performance
Lower performance among downsampled pan-cancer prediction models (Figure 4 ) raises the question: how many cell lines are needed for optimal predictive performance? To estimate needed sample sizes, we developed regularized regression prediction models from a series of randomly downsampled sets of cell lines (ncell lines = 20-300; step size = 10; niterations/step = 30). Performance of downsampled models was evaluated across cell lines of all tissues (pan-cancer) and within the five tissues that are well- Comparisons of pan-cancer and tissue-specific MEKi response prediction models. For each tissue with ≥15 cell lines in both Klijn 2015 and CCLE datasets, a tissue-specific prediction model was trained and tested by considering only cell lines from a given tissue. Regularized regression prediction models were trained on a random selection of 75% of cell lines in CCLE data of a given tissue type (repeated 100 times) and applied to Klijn 2015 cell lines of the same tissue type. Performance was reported using rank correlation between observed and predicted MEKi drug response for each iteration (blue points). Rank correlation for the 30 iterations of MEKi response predictions based on pan-cancer prediction models (Fig. 2) for a given tissue are indicated with red points. Pan-cancer prediction models were trained and tested using many more cell lines than tissue-specific prediction models. A set of pan-cancer prediction models were generated that downsampled the available pan-cancer cell line sets and tissue-specific training sets to equal the sample sizes used for building and evaluating tissue-specific prediction models (gray points). (A-D) Results are shown for all combinations of models trained using CCLE data and applied to Klijn 2015 data. Black horizontal lines: median performance for a given distribution. p1: P-value from a Mann-Whitney U test of the difference between tissue-specific and pan-cancer prediction performances for a given tissue. p2: P-value from a U test of the difference between tissue-specific and downsampled pan-cancer prediction performances.
predicted by pan-cancer prediction models (liver, ovary, lymphoid, stomach, and skin; Supplemental Figure 2B ). For overall pan-cancer prediction performance, we observed an inflection point of largely diminishing returns between 70 and 100 cell lines, depending on the training data (70 cell lines: Figure   5A ,B; 100 cell lines: Figure 5C,D) . However, including additional cell lines further increased performance, albeit with marginal increases beyond n=70. For within-tissue predictions, inclusion of more than 100 cell lines led to diminishing performance returns for liver, lymphoid, stomach, and skin cell lines. Including additional cell lines led to marginally increased performance for lymphoid and stomach cell lines, while predictions for cell lines derived from liver and skin cell lines saturate at n=100 ( Figure 5) . Notably, performance for ovary cell lines showed no inflection point of diminishing returns (Figure 5 ), suggesting ovarian cancers may be well-positioned to benefit from drug response predictions generated from large, pan-cancer datasets. Overall, we find that ≥70-100 samples are needed to provide robust pan-cancer prediction performance in most cases.
DISCUSSION
Pan-cancer drug response predictions that identify shared molecular vulnerabilities in heterogeneous cancer types have the potential to contribute to the advancement of precision oncology approaches. In this study, we highlight tissue-level effects that can bias the interpretation of performance for pan-cancer drug response predictions, show that pan-cancer prediction models provide additional information beyond these tissue-level effects, and demonstrate that pan-cancer prediction models typically outperform tissue-specific prediction models, although the performance advantage usually disappears at comparable sample sizes. We highlight that when pan-cancer approaches to drug response prediction are carefully implemented and interpreted, they are a powerful tool for selecting effective anticancer therapies, not only based on the cancer type but also for individual variability of drug response within a cancer type. This capability is especially valuable for the cancer types that manifest a wide range of responses to MEK inhibition (e.g. lung, liver, and stomach).
Using public pharmacogenomic datasets, we established robust sets of pan-cancer drug response predictions focused on MEK inhibition. We highlight the accuracy of cross-MEKi predictions, which demonstrates MEKi response prediction models are largely agnostic to which MEK inhibitor is being considered, provided they are chemically similar. Ultimately, MEKi prediction models or biomarker panels could reasonably be applied to a preferred MEKi. We also note that the datasets considered here included lymphoid cell lines, a non-epithelial tissue type that is biologically and clinically distinct from the majority epithelial-origin cell lines that dominate both datasets. Importantly, pan-cancer prediction models can accurately predict this highly distinct tissue type. This suggests lymphoid cell lines may respond to MEK inhibition by invoking biological pathways similar to those seen in epithelial cells and therefore genetic or epigenetic variability in other cancer types can account for response in lymphoid cancers.
Although the pan-cancer MEKi response predictions were established in a tissue-agnostic manner (i.e. tissue labels are not provided during the generation of prediction models), we show that betweentissue effects are present in the resulting prediction models. First, prediction performance is variable between tissues, and as a result, a pan-cancer prediction score should not be used to inform treatment for an under-performing tissue. For example, the pan-cancer MEKi response predictions for pancreas, brain, or colorectal tissues provide little more information than knowing the general drug sensitivity of the cancer type. Critically, accurate between-tissue drug response predictions are contributing to the overall success of pan-cancer prediction, even in cases where within-tissue predictions fail (Figure 3B,C; Figure   S2C ). As a result, reports of overall prediction performance across all cancer types in combination will include both between-tissue and within-tissue effects. To account for the between-tissue effects, additional reporting of prediction performance within cancer/tissue types is recommended.
The utility of pan-cancer drug response prediction models will depend on whether they can outperform cancer type-specific prediction models. Based on a systematic evaluation, we found that pancancer prediction models of MEKi response perform similarly or better than tissue-specific prediction models when the former are allowed to use the large sample sizes available from public datasets, indicating that pan-cancer predictions could be useful for precision oncology approaches. However, we further show that pan-cancer prediction models trained with sample sizes comparable to cancer-specific models offer almost no advantage. We emphasize that large public data repositories could offer useful drug response predictions even in cases where a specific cancer type is underrepresented or absent. When assessing needed sample sizes, we show that inclusion of more than 100 cell lines frequently led to diminishing performance returns. This knowledge is useful when designing future experiments and deciding how to invest resources to investigate many other cancer models and drug families.
The results described here are based on an important drug class (MEK inhibitors) and the reproducibility for tissue-scale effects should be tested for additional drug classes. However, we posit that the confounding effects arise from tissue type influencing both drug response and molecular characteristics (e.g. RNA levels and DNA variants). As a result, we emphasize dual considerations for pan-cancer drug response prediction approaches. First, pan-cancer approaches are useful for uncovering common biological mechanisms shared by many cell types when challenged with a drug. Second, tissuelevel effects will likely exert confounding effects and potentially inflate naïvely reported performance. To maximally benefit, pan-cancer approaches must be carefully designed and evaluated to account for tissuelevel effects, and existing pan-cancer drug response predictions reported across a pan-cancer dataset should therefore be interpreted with caution.
With the ever-increasing availability of large pharmacogenomic datasets and introduction of basket clinical trials that select patients based on tumor features rather than cancer type, big data approaches that seek pan-cancer prediction models and biomarker sets will be positioned to match patients with effective treatments. Conceptualizing between-tissue and within-tissue differences of the statistical signal from drug response predictions is essential for contextualizing "precision" in precision oncology, allowing the joint pursuit of both group-based (i.e. tissue class) and individual-based treatment decisions. Thus, accounting for tissue-level effects when designing pan-cancer drug response prediction models or biomarker identification experiments will be required to develop truly personalized treatment based on the characteristics of individual tumors.
METHODS
Cell line annotations and drug response data
Drug response and molecular characterization data were retrieved from two sources: 1) the supplemental material of a prior publication (Klijn 2015) (11) and 2) a tumor cell line database (CCLE) (12) . For Klijn 2015, cell line annotations, including identifiers and primary tumor types, were retrieved from "Supplementary Table 1" in (11) and annotations for CCLE were retrieved from " Supplementary Table   1 " in (12) . Cell line identifiers were connected across datasets and data modalities (i.e. drug response, RNA expression, and DNA variants) by accounting for differential use of upper/lower case characters and/or non-alphanumeric characters; alphabet characters in cell line identifiers were converted to upper case and identifiers were stripped of non-alphanumeric characters. Klijn et al (11) excluded 65 cell lines from analysis due to SNP similarity to other cell lines or uncertainty in cell line origin; we also excluded these cell lines from our analyses ("In Final Analysis Set" column = FALSE; "Supplementary Table 1" in (11) ).
For Klijn 2015, we retrieved drug response data from " Supplementary Table 13 " in (11) . Drug response was provided for 5 total drugs as IC50, the dose at which 50% of cells are non-viable. Lower IC50 values indicate greater sensitivity to a drug than higher values. Among the 5 drugs, we focused on two MEK inhibitors: PD-0325901 (referred to as PD-901) and GDC-0973. For CCLE, drug response data were downloaded in the file "CCLE_NP24.2009_Drug_data_2015.02.24.csv" (database file date: 24
February 2015), which included IC50 data for 24 anti-cancer drugs. We used drug response data for two MEK inhibitors in CCLE: PD-901 and AZD-6244 (trade name: Selumetinib). The natural log of IC50 values were used for feature selection, parameter sweeps, and model generation and evaluation.
RNA expression data
For Klijn 2015, we analyzed expression data from RNA-seq available from two supplemental datasets, designated as protein-coding ("Supplementary Data 1" in (11) ) and non-coding ("Supplementary Data 2" in (11) ). In all, there were 25,984 coding genes and 21,398 non-coding genes after excluding genes that were invariable in expression across all 675 cell lines with RNA data. Expression levels were provided as variance stabilization-transformed read counts from the DESeq package (22) . We further standardized RNA expression data for each gene by linearly scaling values across cell lines to a range between 0 and 1 and shifting the scaled values by subtracting the scaled mean. Gene identifiers in the protein-coding table were converted from Entrez Gene ID to ENSEMBL format using the org.Hs.eg.db package (23) in R, while gene identifiers in the non-coding table were already provided in ENSEMBL format. Once gene identifiers for the Klijn 2015 protein-coding and non-coding datasets were both in ENSEMBL format, we removed genes from the non-coding dataset that were found in the coding dataset.
Following processing described above, the coding and non-coding expression data were merged and treated as a single dataset for downstream analysis. 
DNA variant data
For Klijn 2015, we retrieved single nucleotide polymorphism (SNP) and copy number variation (CNV) mutation data from the associated supplementary material (SNPs: "Supplementary Data 3" in (11); CNVs: "Supplementary Data 4" in (11)). Klijn 2015 SNP and CNV data were identified from SNP microarray analysis (Illumina HumanOmni2.5_4v1). The provided SNPs had been previously filtered to include only missense and nonsense mutations. In all, there were 127,579 unique SNPs across 14, 375 genes for all 675 cell lines with SNP calls. Because any given SNP was rare in the Klijn 2015 dataset, SNPs were mapped up to the gene level; genes then served as binary features (i.e. gene mutated / gene not mutated) without regard to which SNP a gene contained. For Klijn 2015, CNV data were provided based on a gene-by-gene basis as ploidy-adjusted copy number calls from the SNP array data using the PICNIC (24) and GISTIC (25) algorithms. We then classified the provided ploidy-adjusted copy number calls as previous step). We ranked expression variability of each gene based on log variance-to-mean ratio and the included the union of the 3,000 most variable genes from the Klijn 2015 and CCLE datasets in dimensionality reduction analysis shown in Figure 1E .
Model building approach
For each algorithm, we developed prediction models by considering the drug response data for one MEKi along with associated molecular featurese.g. response to PD-901 as assessed by Klijn 2015 compared with the Klijn 2015 molecular features (Figure 2A ). One prediction model was built for each MEKi in both datasets, resulting in four prediction models per algorithm, and models were applied both within and between the Klijn 2015 and CCLE datasets. To assess performance, we established two validation sets: 1) for within-dataset predictions, model performance was reported for the 154 cell lines in common between the two datasets, which were excluded during all aspects of model generation and 2) for between-dataset predictions, performance was reported across all cell lines as no cell lines in the dataset the model was applied to were used during model building. Prediction models were built on 70% of available cell lines (selected randomly), repeated 30 times, and the final predicted drug response of a given cell line was calculated as the average of the 30 models. Note that the remaining 30% of cell lines that were not selected for model training were not used to assess model performance. An example schematic of model training while considering PD-901 in the Klijn 2015 dataset and model application both within and across datasets is shown in Figure 2A .
We established sets of regularized regression, random forest (regression), logistic regression, and random forest (classification) prediction models. Regularized regression and random forest (for both regression and classification) models were trained using the glmnet (26) and randomForest (27) packages in R, respectively. Logistic regression models were trained using the lm() function (family = binomial) in the base installation of R. Regression prediction models (regularized and random forest) were trained on log(IC50) of MEKi response. Classification prediction models (logistic and random forest) were trained on binarized IC50 MEKi response, with IC50 ≤1 defining sensitive cell lines and IC50 > 1 defining resistant.
For within-dataset predictions, the 154 cell lines in common between the Klijn 2015 and CCLE datasets were used as a validation set and excluded from all aspects of model building (i.e. including feature selection, parameter tuning, and model training). For cross-dataset predictions, all cell lines in the dataset not used to train the model were used as a validation set, as no overlapping cell lines were used to develop prediction models. Regression prediction models were trained on 70% of available training cell lines (i.e. cell lines unique to the Klijn 2015 or CCLE datasets). Classification prediction models were trained using a balanced set of sensitive and resistant cell lines: 70% of cell lines of the least populated class (typically sensitive) in the training set were randomly selected and matched with an equal number of randomlyselected cell lines of the more populated class. Model generation with randomly-selected training cell lines was repeated 30 times for both regression and classification predictions. Prediction models were applied to within-dataset and cross-dataset validation sets and the final prediction score was calculated as the average of 30 prediction models.
For regularized regression predictions, we tuned the  and  parameters through a parameter sweep. The  parameter controls whether a ridge regression ( = 0), elastic net (0 <  < 1), or least absolute shrinkage and selection operator (LASSO;  = 1) model is generated. We tested  values from 0 to 1 in 0.1 step increments. The  parameter controls the strength of the penalty on model  values, and  values tested were 0.001, 0.01, 0.1, 1, and 10. For logistic regression and random forest (regression and classification) models, we performed feature selection by LASSO prior to model generation. We performed a parameter sweep to test multiple  values for the LASSO feature selection.  values tested for LASSO feature selection were 1x10 -5 , 5x10 -5 , 1x10 -4 , 5x10 -4 , 0.001, 0.005, 0.01, 0.05, and 0.1. Tuning of  and  parameters was performed by randomly selecting 70% of training cell lines and applying models trained with different parameter sets to the remaining 30% (testing set), repeated for 100 iterations. Note that the validation cell lines were not used for parameter tuning. Optimal parameter sets were selected based on maximum mean performance in the testing set across the 100 iterations. Performance was measured by Spearman's  for regression algorithms and auROC for classification algorithms. Table S1 shows the optimal parameters selected.
We trained tissue-specific prediction models with CCLE data, randomly selecting 75% of cell lines of a given cancer type, and applied the models to Klijn 2015 data for testing. If a cell line overlapping between Klijn 2015 and CCLE was used to build a tissue-specific model, it was excluded from model testing. Tissue-specific prediction models were the only instance in which validation set cell lines (i.e. the 154 cell lines in common between Klijn 2015 and CCLE) were used to build prediction models, as there were fewer overall cell lines available within cancer types. Parameters selected from pan-cancer prediction models were also used for tissue-specific models.
